Response to: 'Quetiapine use: Science or clever marketing?'

Australian and New Zealand Journal of Psychiatry

Volumn 47, Issue 11, 2013, Pages 1086-

  Lambe, John ^a  

^a Regional Rangatahi Adolescent Inpatient Service   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOPICLONE;

ATTENTION DEFICIT DISORDER; CHILD PSYCHIATRY; COMA; DEPRESSION; DRUG EFFICACY; DRUG MARKETING; DRUG OVERDOSE; DRUG SAFETY; DRUG USE; ELEVATED BLOOD PRESSURE; HUMAN; HYPOTENSION; LETTER; OFF LABEL DRUG USE; PRESCRIPTION; PSYCHIATRIST; RESPIRATION DEPRESSION; SCHIZOPHRENIA; SUDDEN CARDIAC DEATH;

ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; HUMANS; MARKETING;

EID: 84887453704     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867413495470     Document Type: Letter

References (5)

1. Heilbronn C, Lloyd B, McElwee P, et al. Quetiapine-related harms are on the rise. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 279-280
2. Kuehn B. FDA panel issues mixed decision on quetiapine in depression and anxiety. Journal of the American Medical Association. 2009 ; 301: 2081-2082
3. MonasterioEMcKeanA (2011) Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. New Zealand Medical Journal124: 24-29. Available at: www.nzma.org.nz/journal/124-1336/4700 (accessed 28 April 2013).
4. Monasterio E, McKean A. Quetiapine use: Science or clever marketing?. Australian and New Zealand Journal of Psychiatry. 2013 ; 47: 96-97
5. Ray W, Chung C, Murray K, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine. 2009 ; 360: 225-235